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ABSTRACT
Aims: To examine the properties of hydrazide compounds shown to inhibit Mycobacterium
tuberculosis. To identify properties that affect efficiency of bacterial inhibition.
Study Design: Utilizing data from previous studies of compounds that inhibit Mycobacterium
tuberculosis, then statistical and pattern recognition methods are applied to identify
interrelationships.
Place and Duration of Study: Department of Chemistry, Durham Science Center, University of
Nebraska at Omaha, from January 2016 to July 2016.
Methodology: Interrelationships of pharmacological properties were identified by use of various
pattern recognition techniques, such as hierarchical cluster analysis and path analysis. Molecular
properties and descriptors for all compounds were determined, with additional characteristics such
as structure scaffolding and functional group position was accomplished. Statistical analysis,
including Pearson r correlation, Mann-Whitney test, one-way ANOVA, Kruskal-Wallis, and
descriptive statistics were determined. Multiple regression analysis of molecular property values
allows prediction of similar compounds. Determination of any numerical outliers was accomplished
by applying Grubb’s test.
_____________________________________________________________________________________________________
*Corresponding author: E-mail: rbartzatt@unomaha.edu;
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Results: Mycobacterium tuberculosis inhibiting compounds contained either an aromatic ring or
were non-aromatic structures (no ring). There was weak negative correlation of MIC to formula
weight. The average formula weight, polar surface area, and Log P, is 183.55 grams/mole, 63.70
A2, and 0.768, respectively. Values of MIC ranged from 14.7 µg/mL to 100 µg/mL. Extent of
bacterial inhibition was similar between aromatics to non-aromatics. No outliers were identified by
Grubb’s test for all values of MIC taken together. Path analysis showed polar surface area to have
most effect on MIC.
Conclusion: The measured level of growth inhibition MIC, showed strong positive relationship to
polar surface area, number of hydroxyl and amine groups, oxygen and nitrogen atoms. Two
aromatic compounds having a pyridine ring were found to be most similar to isoniazid. Aromatic
and non-aromatic compounds showed similar levels of bacterial inhibition overall.

Keywords: Tuberculosis; TB; hydrazides; Mycobacterium tuberculosis.

ABBREVIATIONS
PSA: Polar surface area; FW: Formula weight; nOHNH: Number of hydroxyl and amine groups;
nON: Number of oxygen and nitrogen atoms; MIC: Minimum inhibitory concentration; MDR-TB: Multidrug resistant tuberculosis; XDR-TB: Extensively drug resistant tuberculosis; CNS: Central nervous
system; TDR-TB: Totally drug-resistant tuberculosis.
ethambutol for a period of two months, then
isoniazid and rifampicin only for an additional ten
months [5]. The addition of aspirin in treatment
has been shown to improve mortality rates by
inhibiting complicating infarctions [6]. Children,
especially those less than 1 year of age, are
particularly at risk for CNS tuberculosis [7].

1. INTRODUCTION
The clinical treatment and control of tuberculosis
disease is significantly threatened with the
appearance of multi-drug resistant tuberculosis
(MDR-TB) and extensively drug resistant
tuberculosis (XDR-TB) [1]. The appropriate use
of second-line drugs is required to treat cases of
MDR-TB, and to inhibit the proliferation of XDRTB [1]. The World Health Organization has been
surveilling the rate of resistant tuberculosis in
numerous countries, and an estimate of over four
million cases of MDR-TB is thought to emerge in
2006 [1]. The tuberculosis bacterial infection of
the central nervous system (CNS) accounts for
about 1% of all cases of tuberculosis [2]. The
CNS case of tuberculosis is highly devastating,
causing high mortality and neurological damage
[2]. Measurement of this extra pulmonary
infection within the United States showed that
5% to 10% of these cases involved the CNS [2].
CNS tuberculosis exists primarily as tuberculous
meningitis, and less as encephalitis, intracranial
tuberculoma, or tuberculous brain abscess [2].

Totally drug-resistant tuberculosis (TDR-TB)
have been identified in Italy, Iran, India, and
South Africa [8]. TDR-TB is described as
resistance to all first-line and second-line drugs
utilized in clinical treatment [8]. Extra pulmonary
tuberculosis can coexist simultaneously with
pulmonary tuberculosis [9]. It is the high lipid
content of the bacterial membrane that
contributes to the difficulty of treating
tuberculosis [10]. Patients having latent
tuberculosis infection are not considered to be
contagious to others, but 10% of these cases will
move on to develop active tuberculosis infection
[11]. Various symptoms of CNS involved
tuberculosis infection are the following: brain
abscesses, encephalopathy, encephalitis, and
arteritis [12].

Treatment of CNS associated tuberculosis
infection requires a minimum of 10 months of
treatment [3]. Early treatment of CNS
tuberculosis is vital and dramatically improves
patient outcome [4]. In incidences of tuberculosis
meningitis there is a thick gelatinous exudate in
the proximity of basal cisterns, brainstem, and
cerebellum [2,4]. Treatment of tuberculosis
meningitis is usually followed with treatment
with isoniazid, rifampicin, pyrazinamide, and

With threats such as multi-drug resistant,
extensively drug resistant, and totally drug
resistant tuberculosis, the investigation and
development of new clinical drugs are an urgent
necessity to confront these forms of tuberculosis.
Novel structure scaffolding of compounds have
been evaluated for bacterial inhibition and
potential use as clinical drugs, have been shown
to be effective for inhibiting tuberculosis
2
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[13,14,15]. The design and testing of novel
molecular structures has been shown to be
effective inhibitors of other bacterial infections
such as Staphylococcus aureus [16,17,18], and
Escherichia coli [19,20,21,22]. Clearly, the
investigation of new molecular structures have
benefitted the identification of powerful inhibitors
of bacterial infection. Novel analytical methods to
identify functional groups have accompanied the
generation of novel hydrazide-type drug designs
that assist in synthesis, quality control, and assay
[23]. This study examines the contribution of drug
molecular properties to the effectiveness of their
inhibition of Mycobacterium tuberculosis.

Determination of any numerical outliers was
accomplished by applying Grubb’s test (also
known as extreme studentized deviate)
http://www.graphpad.com/quickcalcs/index.cfm.
Mann-Whitney test, Kruskal-Wallis test, one-way
ANOVA, F and T test, were determined by PAST
version 2.06.

3. RESULTS AND DISCUSSION
3.1 Structure and Properties
The investigation of novel drugs for the treatment
of tuberculosis is a vitally important endeavor
due to the burden of the disease worldwide and
the appearance of multi-drug resistant,
extensively drug resistant, and totally drug
resistant tuberculosis [1,8]. In this study, a group
of novel hydrazide compounds have been
compared to the first-line drug isoniazid for
efficiency
of
Mycobacterium
tuberculosis
inhibition. The effectiveness of inhibition is
measured by in vitro method, with effectiveness
measured as MIC for comparison.

2. METHODOLOGY
2.1 Properties and Molecular Modeling
Molecular properties and descriptors of all
compounds were determined by utilizing
Molinspiration (Molinspiration Cheminformatics,
Nova ulica 61, SK-0026 Slovensky Grob, Slovak
Republic)
http://www.molinspiration.com/cgibin/properties. Additional characteristics was
accomplished through the use of ACD
ChemSketch Modeling v. 12.01 (Advanced
Chemistry Development, 110 Yonge Street,
Toronto
Ontario,
M5C
1T4
Canada,
http://www.molinspiration.com/services/search.
html).

The structures of all compounds tested in vitro
and evaluated [13,14,15], are presented in Fig. 1,
for comparison to the first-line drug isoniazid
(compound 14) and other hydrazide compounds.
Characteristic of all the compounds shown is the
hydrazide group (-C(=O)-NHNH2) that is a
substituent of the molecular structures.
Compounds 1, 2, 3, 4, 8, 9, 10, 13, and 14
(isoniazid)
have
aromatic
ring
(contain
conjugated
planar
ring
systems),
with
compounds 8, 13, and 14 being heterocyclic
compounds having a nitrogen atom substitution
within the ring (see Fig. 1).

2.2 Pattern Recognition and Multivariate
Analysis
Numerical properties can demonstrate underlying
patterns and relationships which can be identified
by use of various pattern recognition techniques.
Hierarchical cluster analysis cluster analysis was
performed by KyPlot version 2.0 beta 15
(copyright Koichi Yoshioka 1997-2001). Various
statistical tests were performed by PAST version
2.06 (copyright Oyvind Hammer, D.A.T. Harper
1999-2008). Path analysis was determined by
utilzing OpenStat (copyright William Miller,
September 11, 2008).

Compounds 5, 6, 7, and 11 have aliphatic chains
(chain of –CH2-), albeit compound 5 has a
terminal bromine atom. Aliphatic groups are
nonpolar and hydrophobic, with hydrophobicity
increasing with increasing number of C atoms in
the hydrocarbon chain. Hydrophobicity reduces
aqueous solubility and increases lipophilic
character. More lipophilic character is generally
viewed as increasing the ability of a drug to
penetrate the membrane bilayer. Each of these
compounds have the hydrazide group (-C(=O)NHNH2). Compounds 1, 2, 4, 9, and 10 have
substituents covalently bonded to an aromatic
ring: methyl-, methyl-, chloro-, 2-methylpropyl-,
and acetate, respectively. Compounds 12 has
two hydrazide groups. All other compounds have
only a single hydrazide group.

2.3 Various Statistical Analysis of Data
Statistical analysis, including Pearson r
correlation and descriptive statistics were
accomplished
by
Microsoft
EXCEL
v.14.0.6112.5000 (EXCEL Professional plus
2010). Multiple regression analysis of molecular
property values was accomplished by GraphPad
Instat version 3.00 (GraphPad Software, Inc.,
San Diego, California USA; www.graphpad.com).
3
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Fig. 1. Compounds previously shown to inhibit the growth of Mycobacterium tuberculosis
[13,14,15]. All compounds possess the hydrazide group (-C(=O)NHNH2). Compounds 1, 2, 3, 4,
8, 9, 10, 13, and 14 are aromatic organic compounds. Compounds 5, 6, 7, 11, and 12 are nonaromatic organic compounds. Compound 12 bears two hydrazide functional groups
The comparison of aromatic and nonaromatic
molecular scaffolding for delivery of the
hydrazide group will elucidate the effects upon
the molecular properties of the drug, such as:
Log P, polar surface area, formula weight,
number of hydroxyl, and number of amine
groups.

(i.e. a qualitative concept for how drug like a
compound
in
respect
to
factors
like
bioavailability). Various criteria have been
developed to screen a potential drug for drug
likeness, such as the rule of five, which states
that poor absorption or permeation is more likely
for a drug candidate when there are more than
[24]: 1) Five hydrogen bond donors; 2) Ten
hydrogen bond acceptors; 3) The molecular
weight is greater than 500; and 4) Calculated Log

In turn, these aspects of the molecular structure
have been shown to influence the drug likeness
4
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numerical values, determined by Grubb’s test
[25].

P (CLogP) is greater than 5. Zero violations of
the rule of five indicates favorable drug likeness,
with favorable absorption or permeation [24].
Shown in Table 1, compound 12 demonstrates
only one violation of the rule of five, however, all
other compounds demonstrate zero violations.
This outcome indicates that these aromatic and
nonaromatic compounds will have favorable
absorption and membrane permeation.

Interestingly, there appears to be no advantage
overall in MIC values of either type, aromatic or
nonaromatic, compared to the other. Although
the MIC values vary widely individually, from 14.7
µg/mL (isoniazid) to 100 µg/mL (9 and 10), when
comparing aromatic and nonaromatic group
values of MIC, the F and T test and one-way
ANOVA show that the two group means of MIC
are equal (P =.82 and P= .82, respectively). In
addition, the two group values in MIC have equal
medians by the Mann-Whitney test (P = .68) and
Kruskal-Wallis test (P = .64) [25].

The molecular properties and MIC (compound
concentration when only 50% of the bacteria in
culture are viable) of all compounds are
presented for comparison in Table 1. A
multivariate table permits the pattern recognition
of underlying relationships as well as statistical
analysis. For all these hydrazide compounds the
average MIC, formula weight, Log P, and polar
surface area are 46.15 µgram/mL, 183.55, 0.767,
and 63.70 Angstroms2, respectively. Notably,
only compound 12 has one violation of the rule of
five, whereas, all the others have zero violations,
indicating favorable drug likeness and favorable
drug absorption.

Therefore, the overall effectiveness of these
aromatic compounds is considered statistically to
be essentially equal overall to the nonaromatic
compounds. However, clearly there are
substantial improvements in bacterial inhibition,
indicated by MIC values, from individual drug
scaffolding and design. For example, clearly for
aromatic compounds the drugs 14, 8, 3, and 13
have a substantially lower MIC than compounds
9 and 10. Likewise, for MIC values for
nonaromatic compounds, drugs 11, 6, and 7
have substantially smaller MIC than for
compound 12 (see Fig. 2).

The addition of a second hydrazide group
(-C(=O)-NHNH2) onto the scaffold for compound
12 increased (doubled) the number of
hydrogen bond donors (-NHn, -OH) and
hydrogen bond acceptors (oxygen and nitrogen
atoms).

This study comparing aromatic scaffolding and
non-aromatic scaffolding clarifies structural
features
important
for
potential
clinical
application. Even though the aromatic type
compounds are overall statistically equal to
nonaromatic compounds, it is still very easy to
see structure substituents, size in formula weight,
Log P, and polar surface area can still be
selected to increase effectiveness in bacterial
inhibition and smaller MIC.

These 14 compounds have some level of
similarity in molecular properties but vary in
values of MIC. For example, applying the
Grubb’s test for detecting outliers [25], no outliers
were found in numerical values of Log P, formula
weight, and MIC. Compound 12 is an outlier for
values of polar surface area, number of –OH and
–NHn, as well as number of oxygen & nitrogen
atoms. Interestingly, the sum of five of the
molecular properties (excluding MIC and rule of
five) show similar means for these 14
compounds, a result calculated by one-way
ANOVA analysis (P = 1.0) [25].

For example, in the aromatic group of
compounds the three lowest MIC occur for
compounds 8, 13, and 14. All three of these
compounds possess a single pyridine ring with
the hydrazide group covalently bonded.
Compounds 8 and 13 have a single methylene
bridge and 2 methylene bridge groups,
respectively. Compounds 8 and 13 are two
members of a homologous series having a
constant unit of –CH2- [26]. For many series of
compounds lengthening by adding –CH2- to a
chain produces an increase in pharmacological
effects [26]. Although compound 13 has greater
formula weight than that of compound 8, the
value of MIC does not increase with an increase
in formula weight.

All 14 compounds have been tested by in vitro
methods for the magnitude of growth inhibition of
Mycobacterium tuberculosis [13,14,15]. The
individual MIC values for each compounds is
presented in Fig. 2 bar graph for comparison to
isoniazid and other compounds. The overall
mean for the MIC values obtained from aromatic
compounds is 47.66 µg/mL, which is very close
to the average MIC for nonaromatic compounds
to be 43.43 µg/mL. The overall values of all
MIC values taken together have no outlier in
5
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Table 1. Molecular properties and MIC for compounds
Compound MIC
Formula Log P
(microgram weight
per milliliter)
1
2
3
4
5
6
7
8
9
10
11
12
13
14 isoniazid

47.1
38.6
28
47.1
47.1
26.7
26.7
26.7
100
100
16.7
100
26.7
14.7

150.2
150.2
150.2
170.6
209.1
242.41
256.434
151.17
220.32
194.19
214.33
158.16
165.2
137.14

0.721
0.769
-0.226
0.998
0.258
4.46
4.97
-1.463
1.874
0.372
3.449
-3.52
-0.945
-0.969

Polar
surface
area
(Angstroms2)
55.121
55.121
55.121
55.121
55.121
55.121
55.121
68.013
55.121
81.426
55.121
110.24
68.013
68.013

Number
of –OH
and
-NHn
3
3
3
3
3
3
3
3
3
3
3
6
3
3

Number of
oxygen and
nitrogen
atoms
3
3
3
3
3
3
3
4
3
5
3
6
4
4

Violations
of rule of
5
0
0
0
0
0
0
0
0
0
0
0
1
0
0

A2 = Angstroms2

Fig. 2. Comparison of MIC for compounds 1 to 14 (see Fig. 1). Aromatic compounds have at
least one aromatic ring. Non-aromatics possess no aromatic ring. Statistical analysis is
administered to compare results of aromatic and non-aromatic
group [25]. The unsupervised classification
method works by locating hidden structures in
unlabeled data by segmentation or clustering
techniques.

3.2 Numerical Analysis of Properties
Pattern recognition is the process of classifying
multivariate data into objects or groups based on
key properties. There are two classification
methods in pattern recognition: supervised and
unsupervised classification [25]. The supervised
classification of input data into the pattern
recognition method uses supervised learning
algorithms that create classifiers based on
training data. The classifier then accepts input
data and will assign the object to appropriate

Hierarchical cluster analysis is a method of
cluster analysis which seeks to build a hierarchy
of clusters [25]. Objects are classified into
clusters containing members having highest
similarity based on properties collected into a
multivariate table (see Table 1). Hierarchical
cluster analysis of Table 1 properties, produces
6
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the vertical dendrogram results in Fig. 3.
Conditions of cluster analysis are single-linkage
clustering (similarity of two clusters is based on
the similarity of their members) and Euclidean
distance (straight-line distance between two
points) [25].

connection to MIC, having path coefficient of
109.144. Interestingly, the lowest value at 85.214 is number of oxygen & nitrogen atoms.
The second to lowest is number of –OH & -NHn
groups at -29.572. Path analysis can reveal the
possible causal connections of properties, which
in turn can indicate causality to MIC.

Fig. 4. Path analysis of molecular properties
and their association to MIC values, to
determine the most influential property.
Polar surface area is clearly shown to have
greatest influence to MIC with path coefficient
of 109.144. Properties quantifying oxygen
atoms, nitrogen atoms, hydroxyl groups, and
amine groups are clearly of substantially
lesser influence (smaller path coefficients)

Fig. 3. Vertical dendrogram showing results
of hierarchical cluster analysis of molecular
properties shown in Table 1. Note initial node
A is divided to distinguish compound 12 from
the all the remaining compounds. Node B
encompasses all other compounds save for
compound 12 and 10 that are distinguished.
Within node B the clusters show compounds
6, 7, and 11 are most similar (with compound
9 distinct). Node C encompasses cluster 8,
13, and 14 to be most similar; with cluster 1,
2, 4, 3, and 5 to be most similar

3.2.1 Multiple
regression
prediction

analysis

for

Multiple regression is a statistical tool that allows
you to examine how multiple independent
variables are related to a dependent variable.
Once you have identified how these multiple
variables relate to your dependent variable, you
can take information about all of the independent
variables and use it to make much more powerful
and accurate predictions concerning these
variables. It is used when we want to predict the
value of a variable based on the value of two or
more other variables [25].

Beginning with node A containing all compounds,
they are distinguished into compound 12
(separate from all others), compound 10, and
node B. Under node B, there is further distinction
into compound 9 and cluster of compounds 6, 7,
and 11 (most similar). Under node C further
distinction and classification by similarity shows
compounds 8, 13, and 14 (most similar).
Clustering
continues
with
most
similar
compounds 1, 2 (most similar), 4, 3, and 5. This
method of numerical analysis shows, based on
property values, which compounds are most
similar and potentially equal in activity [26].

To form a model for prediction and elucidation of
relations among variables, multiple regress is
performed utilizing properties in Table 1. The
result is shown in equation (1) where: FW is
formula weight, Log P is partition coefficient, PSA
is polar surface area, nOHNH is number of –OH
& -NHn groups, and nON is number of oxygen &
nitrogen atoms.

Path analysis is an extension of multiple
regression. Its aim is to provide estimates of the
magnitude and significance of hypothesized
causal connections between sets of properties
[27]. Path analysis of properties in Table 1
produced causal connections to MIC presented
in Fig. 4. By this analysis, clearly the polar
surface area property has highest causal

FW = 98.658 + 18.363(Log P) + 8.473(PSA)
– 36.858(nOHNH) – 98.129(nON)
(1)
For equation (1), the R2 value is 0.7759,
indicating 77.59% of the variance in formula
7
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weight is explained by the model. In this model,
the constant 98.658 and Log P make the most
significant contribution to the model. Here the
conclusion of the multiple regression is the
relationship of various properties to the formula
weight.

study identifies the molecular properties
and structural features of compounds that
enable the effective inhibition of Mycobacterium
tuberculosis.

Utilizing equation (1), it would be possible to
predict favorable values of pharmacological
important properties for perspective drug
candidates. The design of new potential drugs
can be enhanced by targeting the characteristic
molecular structure of previously successful
compounds.
The
design
of
additional
tuberculostatic drugs is highly important, the
appearance of multiple multi-drug resistant
tuberculosis and extensively drug resistant
tuberculosis pose a genuine threat to social
health.

It is not applicable.

Tuberculosis is a serious health threat and is
thought to cause up to 1.5 million deaths
annually [28]. The emergence of drug-resistant
strains of tuberculosis and with the HIV coinfection the incidence of this disease has
increased [28]. Almost one-third of the world’s
population is infected with Mycobacterium
tuberculosis [29,30]. Annually, up to 8.8 million
patients are newly diagnosed with an active
infection of tuberculosis [30]. The current first-line
drugs for treatment (isoniazid, rifampin,
pyrazinamide, ethambutol) must be taken for up
to 6 months to achieve high level of cure rates
(>95%) [30]. Clearly, the investigation and
pursuit of new drugs is vital for the clinical
treatment of tuberculosis.
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